Literature DB >> 24278582

Skin Sensitization Study of Bee Venom (Apis mellifera L.) in Guinea Pigs.

Sang Mi Han1, Gwang Gill Lee, Kyun Kyu Park.   

Abstract

Bee venom (Apis mellifera L., BV) has been used as a cosmetic ingredient for antiaging, anti-inflammatory and antibacterial functions. The aim of this study was to access the skin sensitization of BV, a Buehler test was conducted fifty healthy male Hartley guinea pigs with three groups; Group G1 (BVsensitization group, 20 animals), group G2 (the positive control-sensitization group, 20 animals), and group G3 (the ethyl alcohol-sensitization group, 10 animals). The exposure on the left flank for induction was repeated three times at intervals of one week. Two weeks after the last induction, the challenge was performed on the right flank. No treatment-related clinical signs or body weight changes were observed during the study period. The average skin reaction evaluated by erythema and edema on the challenge sites and sensitization rate in the BV-sensitization group at 30 hours were 0.0 and 0%, respectively, which are substantially low compared with in positive control group (average skin reaction: 0.55, sensitization rate: 40%) and identical with in vehicle control group, representing a weak sensitizing potential. The average skin reaction and sensitization rate observed at 54 hours were 0.0 and 0% in the BV-sensitization group, respectively, and 0.25 and 20% in the positive control group, respectively. It was concluded that BV classified to Grade I, induced no sensitization when tested in guinea pigs and may provide a developmental basis for a cosmetic ingredient or external application for topical uses.

Entities:  

Keywords:  Bee venom; Buehler test; Guinea pigs; Skin sensitization

Year:  2012        PMID: 24278582      PMCID: PMC3834403          DOI: 10.5487/TR.2012.28.1.001

Source DB:  PubMed          Journal:  Toxicol Res        ISSN: 1976-8257


INTRODUCTION

Bee venom (BV) from the honeybee (Apis mellifera L.) possesses a variety of different peptides including melittin, apamin, adolapin and mast cell degranulating peptide (Son . In addition, it contains biologically active amines (histamine, epinephrine) and a few non-peptide components including lipids, carbohydrates and free amino acids (Lariviere and Melzack, 1996). BV has been used as a complementary medicine to treat such conditions as rheumatoid arthritis (Park ; Son and cancerous tumors (Jang ; Ip ; Wang ; Soman ; Park . Recently BV also has been used as a cosmetic ingredient for antiaging, anti-inflammatory and antibacterial functions. Pure BV is generally obtained by collecting a large amount of BV by electric stunning using a BV collector without harming the honey bees, removing impurities from the collected BV, and lyophilizing the resultant. We previously reported skin photoprotective action of BV through reduction of protein levels of matrix metalloproteinases which are main contributors to photoaging processes was found in our another study (Han . For the purpose of accessing BV further as a cosmetic ingredient and a potential external application for topical uses, we performed studies for the skin sensitization. Assessment of skin sensitization potential is an important part of any toxicology program for new consumer products to safe guard human beings against the possible adverse effects (Vinardell and Mitjans, 2008).

MATERIALS AND METHODS

Colonies of natural honeybees (Apis mellifera L.) used in this study were maintained at the National Academy of Agricultural Science (NAAS), Suwon, Korea. BV was collected by a bee venom collecting device (Chunglin, Korea) in a sterile manner under strict laboratory conditions. In brief, the bee venom collector was placed on the hive, and the bees were given enough electric shock to cause them to sting a glass plate from which dried bee venom was later scraped off. The collected venom was purified by method of Han . Purified BV was stored in a refrigerator for later use. Experiments were performed on fifty healthy, young 5 weeks old male guinea pig (Hartley Guinea pig, weight 318~369 g, Samtako Bio, Osan, Korea). Animals were visually examined at the time of receipt and housed for 11 days in the animal room. They were maintained under controlled environmental conditions (temperature 23 ± 3℃; relative humidity 55 ± 10%; 12 : 12 hours light : dark cycle; ventilation rate 10~20/hours; illumination 150~300 lux), providing ad libitum access to a commercial guinea pigs diet (Harlan Teklad, USA) and water. All procedures were approved by the Institutional Animal Care and Use Committee (IACUC) in Korea Institute of Toxicology, KRICT and conducted in the facility approved by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International. Dose levels for the study were decided the result of the preliminary study (not shown). HCA (Hexylcinnamaldehyde, CAS no. 101- 86-0, Sigma) solution of 10% was chosen for positive control. Table 1 is showed group assignment of animals. The induction and challenge BV was dissolved in vehicle at 10 mg/ml for the administration. The positive control was dissolved in 80% ethyl alcohol for the induction and in acetone for the challenge, respectively. Induction was performed on the left flank and challenge on the right flank. To use topical (patch) application, application site was cleared of hair (closely clipped). A cotton pad (2 × 2 cm2) was fully loaded with test or control item solution and held on the application site by an occlusive patch for 6 hours exposure, the patch was removed and the application site was washed with tap water. The induction period was once a week total three times. The challenge period was 2 weeks after the last induction.
Table 1.

Experiment group assignment in guinea pigs

GroupNo of animalAdministration

InductionChallenge

G1a)20BVBV
G2b)20HCAd)HCA
G3c)10Ethyl alcoholHCA

a)Group G1: sensitized with BV and challenged with BV.

b)Group G2: sensitized with the HCA and challenged with HCA.

c)Group G3: sensitized with ethyl alcohol and challenged with HCA.

d)HCA(Hexylcinnamaldehyde) is positive control.

Individual weight of guinea pigs was determined and they were observed for any clinical signs. Mortality was recorded during the observation period. The challenge sites were cleared of hair 21 hours after removing the patch. Approximately 3 hours later and 24 hours later, skin responses were recorded according to the grading scale as Table 2 and 3. After the observation of skin response, all animals were euthanized with CO2 overdose.
Table 2.

Evaluation of primary skin response

ScoreSkin response

0No visible change
1Dispersed or blotchy erythema
2Moderate diffused erythema
3Marked erythema and oedema
Table 3.

Classification of skin sensitization level

Sensitization rate (%)GradeClassification

1~80IWeak
9~28IIMild
29~64IIIModerate
65~80IVStrong
81~100VExtreme
Experiment group assignment in guinea pigs a)Group G1: sensitized with BV and challenged with BV. b)Group G2: sensitized with the HCA and challenged with HCA. c)Group G3: sensitized with ethyl alcohol and challenged with HCA. d)HCA(Hexylcinnamaldehyde) is positive control. Evaluation of primary skin response Classification of skin sensitization level The body weights collected during the study were analysed with F-test to examine variance homogeneity. The t-test was conducted to determine whether the BV-sensitization group was significantly different from the vehicle control-sensitization group. The level of significance was taken as P < 0.05 or 0.01. Statistical analysis was performed by using Path/Tox System (ver 4.4.4, Xybion medical Systems Corporation, USA) according to SOPs of KIT, KRICT.

RESULTS

The BV application to the guinea pig skin revealed no appreciable clinical signs throughout the observation period of 31 days and there was no mortality seen (Table 4). Also there was no significant change in body weight of the guinea pigs from BV application during the observation period (Fig. 1). In the skin sensitization test, no fur, erythema, scab or any other reactions were observed in BV (Table 5).
Table 4.

Mortality of skin sensitization in guinea pigs

GroupDosing PhaseFinal mortality

1 day≤ 1 weeks≤ 2 weeks≤ 3 weeks≤ 4 weeks

G1a)000000/20
G2b)000000/20
G3c)000000/10

a)Group G1: sensitized with BV and challenged with BV.

b)Group G2: sensitized with the HCA and challenged with HCA.

c)Group G3: sensitized with ethyl alcohol and challenged with HCA.

Fig. 1.

Body weights of skin sensitization in guinea pigs. Group G1; sensitized with BV and challenged with BV, Group G2; sensitized with the HCA and challenged with HCA, Group G3: sensitized with ethyl alcohol and challenged with HCA.

Table 5.

Clinical signs of skin sensitization in guinea pigs

GroupG1a)G2b)G3c)



#d)%#%#%

Fur, Hair, Coat loss of fur0/20e)010/20500/100
Skin Scab0/20020/201000/100
Erythema0/20020/201000/100

a)Group G1: sensitized with BV and challenged with BV.

b)Group G2: sensitized with the HCA and challenged with HCA.

c)Group G3: sensitized with ethyl alcohol and challenged with HCA.

d)Number of animals.

e)Number of animals with sign/Total of animals observed.

Approximately 30 and 54 hours from the start of the challenge application (24 and 48 hours from the removing patch), the skin reaction was observed. The average skin reaction scores in the groups BV, positive control, and ethyl alcohol at 30 hours were 0.0, 0.55, and 0.0, respectively (Table 6). The sensitization rates at the same time point were 0, 40, and 0%, respectively. The average skin reaction scores in the group BV, positive control, and negative control at 54 hours were 0.0, 0.25, and 0.0, respectively. The sensitization rates at the same time point were 0, 20, and 0%, respectively.
Table 6.

Results of skin sensitization in guinea pigs

GroupNo. of animalsAverage sensitization scorea)Sensitization rateb)Maximization grade



30 h54 h30 h54 hGradeClassification

G1c)200.00.00%0%IWeak
G2d)200.550.2540%20%IIIModerate
G3e)100.00.00%0%IWeak

a)Average sensitization score = (ΣSensitization score of each animal)/Number of animals observed.

b)Sensitization rate(%) = (Number of animals with positive response/Number of animals observed) × 100.

c)Group G1: sensitized with BV and challenged with BV.

d)Group G2: sensitized with the HCA and challenged with HCA.

e)Group G3: sensitized with ethyl alcohol and challenged with HCA.

Mortality of skin sensitization in guinea pigs a)Group G1: sensitized with BV and challenged with BV. b)Group G2: sensitized with the HCA and challenged with HCA. c)Group G3: sensitized with ethyl alcohol and challenged with HCA.

DISCUSSION

BV therapy is a treatment modality that may be thousands of years old (Piek, 1986) and involves the application of live bee stings to patient skin or, in more recent years, the injection of BV into the skin with a hypodermic needle (Castro ; Baek . BV also has been reported to be effective in treating allergies, scarring, burns, and skin diseases (Han . The EU Research Project CAESAR was responsible for developing robust QSARs for five toxicological endpoints of regulatory importance, one of which was skin sensitization. A skin sensitizer is a substance that will induce an allergic response following skin contact. Substances are classed as skin sensitizers, if there is evidence in humans that the substance can induce sensitization by skin contact in a substantial number of persons, or where there are positive results from an appropriate animal test (Chaudhry . This study was performed to determine the skin sensitively of BV. In Buehler test of a skin sensitization test using guinea pigs, the induction with patch application was repeated three times at intervals of one week and the challenge application was performed 2 weeks after the last induction application. The average skin reaction score and sensitization rate in the BV group at 30 hours were 0 and 0%, respectively. The skin response on the same site at 54 hours showed the average skin reaction of 0 and sensitization rate of 0%. Clinical signs of skin sensitization in guinea pigs a)Group G1: sensitized with BV and challenged with BV. b)Group G2: sensitized with the HCA and challenged with HCA. c)Group G3: sensitized with ethyl alcohol and challenged with HCA. d)Number of animals. e)Number of animals with sign/Total of animals observed. Results of skin sensitization in guinea pigs a)Average sensitization score = (ΣSensitization score of each animal)/Number of animals observed. b)Sensitization rate(%) = (Number of animals with positive response/Number of animals observed) × 100. c)Group G1: sensitized with BV and challenged with BV. d)Group G2: sensitized with the HCA and challenged with HCA. e)Group G3: sensitized with ethyl alcohol and challenged with HCA. In conclusion, skin sensitization level of BV was classified as Grade I. BV is not considered to induce skin sensitization since the skin sensitization ratio was 0%. Since BV has recently been reported to possess antibacterial effect against acne-inducing bacteria and effect of wound healing (Han ; Han , it is timely and appropriate to endeavour toxicological approach to BV for the possible adverse effects with the intent of using BV in cosmetic and medical applications.
  13 in total

1.  Antiarthritic effect of bee venom: inhibition of inflammation mediator generation by suppression of NF-kappaB through interaction with the p50 subunit.

Authors:  Hye Ji Park; Seong Ho Lee; Dong Ju Son; Ki Wan Oh; Ki Hyun Kim; Ho Sueb Song; Goon Joung Kim; Goo Taeg Oh; Do Young Yoon; Jin Tae Hong
Journal:  Arthritis Rheum       Date:  2004-11

2.  The bee venom test: a new tonic-pain test.

Authors:  W R Lariviere; R Melzack
Journal:  Pain       Date:  1996-08       Impact factor: 6.961

3.  Bee venom induces apoptosis and inhibits expression of cyclooxygenase-2 mRNA in human lung cancer cell line NCI-H1299.

Authors:  Mi-Hyeon Jang; Min-Chul Shin; Sabina Lim; Seung-Moo Han; Hi-Joon Park; Insop Shin; Ji-Suk Lee; Kyoung-Ah Kim; Ee-Hwa Kim; Chang-Ju Kim
Journal:  J Pharmacol Sci       Date:  2003-02       Impact factor: 3.337

4.  Anti-cancer effect of bee venom in prostate cancer cells through activation of caspase pathway via inactivation of NF-κB.

Authors:  Mi Hee Park; Myoung Suk Choi; Dong Hoon Kwak; Ki-Wan Oh; Do Young Yoon; Sang Bae Han; Ho Sueb Song; Min Jong Song; Jin Tae Hong
Journal:  Prostate       Date:  2010-11-17       Impact factor: 4.104

5.  Global QSAR models of skin sensitisers for regulatory purposes.

Authors:  Qasim Chaudhry; Nadège Piclin; Jane Cotterill; Marco Pintore; Nick R Price; Jacques R Chrétien; Alessandra Roncaglioni
Journal:  Chem Cent J       Date:  2010-07-29       Impact factor: 4.215

6.  A phase I study of the safety of honeybee venom extract as a possible treatment for patients with progressive forms of multiple sclerosis.

Authors:  Henry J Castro; Julia I Mendez-Lnocencio; Berna Omidvar; Jemal Omidvar; John Santilli; H S Nielsen; Alfred P Pavot; John R Richert; Joseph A Bellanti
Journal:  Allergy Asthma Proc       Date:  2005 Nov-Dec       Impact factor: 2.587

Review 7.  Therapeutic application of anti-arthritis, pain-releasing, and anti-cancer effects of bee venom and its constituent compounds.

Authors:  Dong Ju Son; Jae Woong Lee; Young Hee Lee; Ho Sueb Song; Chong Kil Lee; Jin Tae Hong
Journal:  Pharmacol Ther       Date:  2007-05-06       Impact factor: 12.310

8.  The role of mitochondria in bee venom-induced apoptosis in human breast cancer MCF7 cells.

Authors:  Siu-Wan Ip; Shin-Shin Liao; Shuw-Yuan Lin; Jing-Pin Lin; Jai-Sing Yang; Meng-Liang Lin; Guang-Wei Chen; Hsu-Feng Lu; Meng-Wei Lin; Sang-Mi Han; Jing-Gung Chung
Journal:  In Vivo       Date:  2008 Mar-Apr       Impact factor: 2.155

9.  Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth.

Authors:  Neelesh R Soman; Steven L Baldwin; Grace Hu; Jon N Marsh; Gregory M Lanza; John E Heuser; Jeffrey M Arbeit; Samuel A Wickline; Paul H Schlesinger
Journal:  J Clin Invest       Date:  2009-08-10       Impact factor: 14.808

10.  Melittin, a major component of bee venom, sensitizes human hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating CaMKII-TAK1-JNK/p38 and inhibiting IkappaBalpha kinase-NFkappaB.

Authors:  Chen Wang; Taoyong Chen; Ning Zhang; Mingjin Yang; Bai Li; Xiang Lü; Xuetao Cao; Changquan Ling
Journal:  J Biol Chem       Date:  2008-12-12       Impact factor: 5.486

View more
  3 in total

Review 1.  Cosmetic Applications of Bee Venom.

Authors:  Aida A Abd El-Wahed; Shaden A M Khalifa; Mohamed H Elashal; Syed G Musharraf; Aamer Saeed; Alfi Khatib; Haroon Elrasheid Tahir; Xiaobo Zou; Yahya Al Naggar; Arshad Mehmood; Kai Wang; Hesham R El-Seedi
Journal:  Toxins (Basel)       Date:  2021-11-18       Impact factor: 4.546

2.  Melittin, a honeybee venom‑derived antimicrobial peptide, may target methicillin‑resistant Staphylococcus aureus.

Authors:  Ji Hae Choi; A Yeung Jang; Shunmei Lin; Sangyong Lim; Dongho Kim; Kyungho Park; Sang-Mi Han; Joo-Hong Yeo; Ho Seong Seo
Journal:  Mol Med Rep       Date:  2015-09-01       Impact factor: 2.952

Review 3.  Bee Products in Dermatology and Skin Care.

Authors:  Anna Kurek-Górecka; Michał Górecki; Anna Rzepecka-Stojko; Radosław Balwierz; Jerzy Stojko
Journal:  Molecules       Date:  2020-01-28       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.